SS
HCWB icon

SBI Securities’s HCW Biologics HCWB Stock Holding History

SBI Securities’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 4131
2026
Q1 		– Hold
0
– – – 4086
2025
Q4 		– Hold
0
– -$4 – 4115
2025
Q3 		– Sell
-1
Closed -$26 – 4119
2025
Q2 		$24 Buy
+1
New +$44 ﹤0.01% 3876

Other funds holding HCWB

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities's HCWB Position: Q2 2026 in Review

SBI Securities held its HCW Biologics (HCWB) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4131.

SBI Securities first reported a position in HCWB in Q2 2025 and has held it in 1 quarter since. The position peaked at $24 in Q2 2025. 7 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • SBI Securities held 0 shares of HCW Biologics worth $0 as of Q2 2026.
  • SBI Securities left its HCW Biologics share count unchanged in Q2 2026.
  • HCW Biologics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #4131 holding.
  • SBI Securities first reported a position in HCW Biologics in Q2 2025 and has held it in 1 quarter since.
  • SBI Securities's HCW Biologics position peaked at $24 in Q2 2025.
  • 7 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.